PMID- 16791116
OWN - NLM
STAT- MEDLINE
DCOM- 20060824
LR  - 20200930
IS  - 1525-4135 (Print)
IS  - 1525-4135 (Linking)
VI  - 42
IP  - 4
DP  - 2006 Aug 1
TI  - Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS 
      clinical trials group study.
PG  - 450-4
AB  - BACKGROUND: Peripheral neuropathy that complicates HIV nucleoside reverse 
      transcriptase inhibitor (NRTI) therapy is likely caused by mitochondrial injury. 
      Mitochondria play a central role in regulating oxidant stress. We explored the 
      relationships between oxidant stress and NRTI-induced peripheral neuropathy. 
      METHODS: The AIDS Clinical Trials Group (ACTG) studied the cases of 384 
      antiretroviral-naive individuals randomized to receive didanosine/stavudine or 
      zidovudine/lamivudine, plus efavirenz, nelfinavir, or both. The participants were 
      followed for up to 3 years. Peripheral neuropathy was ascertained by signs and 
      symptoms. We performed a case-control study of ACTG 384 participants. Peripheral 
      neuropathy cases and nonneuropathy control subjects were selected from 
      didanosine/stavudine recipients. Alternate control subjects were selected from 
      zidovudine/lamivudine recipients who developed peripheral neuropathy. Oxidant 
      stress was assessed by quantifying F2-isoprostanes (F2-IsoPs) in cryopreserved 
      plasma. RESULTS: Seventy-five cases, 71 control subjects, and 18 alternate 
      control subjects were identified. The median baseline F2-IsoP values were 53 
      (interquartile range [IQR], 40-85), 57 (IQR, 41-77), and 53 (IQR, 47-101) pg/mL, 
      respectively, and did not differ between cases and control subjects (P = 0.78) or 
      alternate control subjects (P = 0.60). Changes in F2-IsoPs from baseline to time 
      of peripheral neuropathy did not differ significantly between cases (median, 10 
      [IQR, -17 to 26] pg/mL) and control subjects (median, 4 [IQR, -11 to 17] pg/mL; P 
      = 0.48) or alternate control subjects (median, 1 [IQR, -48 to 10] pg/mL; P = 
      0.21). CONCLUSIONS: Peripheral neuropathy that complicates antiretroviral therapy 
      with NRTIs was not associated with increased systemic oxidant stress assessed by 
      plasma F2-IsoPs.
FAU - Hulgan, Todd
AU  - Hulgan T
AD  - Vanderbilt University School of Medicine, Nashville, TN 37203, USA. 
      todd.hulgan@vanderbilt.edu
FAU - Hughes, Michael
AU  - Hughes M
FAU - Sun, Xin
AU  - Sun X
FAU - Smeaton, Laura M
AU  - Smeaton LM
FAU - Terry, Erin
AU  - Terry E
FAU - Robbins, Gregory K
AU  - Robbins GK
FAU - Shafer, Robert W
AU  - Shafer RW
FAU - Clifford, David B
AU  - Clifford DB
FAU - McComsey, Grace A
AU  - McComsey GA
FAU - Canter, Jeffery A
AU  - Canter JA
FAU - Morrow, Jason D
AU  - Morrow JD
FAU - Haas, David W
AU  - Haas DW
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*adverse effects/therapeutic use
MH  - Case-Control Studies
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Oxidative Stress
MH  - Peripheral Nervous System Diseases/*chemically induced
MH  - Randomized Controlled Trials as Topic
EDAT- 2006/06/23 09:00
MHDA- 2006/08/25 09:00
CRDT- 2006/06/23 09:00
PHST- 2006/06/23 09:00 [pubmed]
PHST- 2006/08/25 09:00 [medline]
PHST- 2006/06/23 09:00 [entrez]
AID - 10.1097/01.qai.0000226792.16216.1c [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):450-4. doi: 
      10.1097/01.qai.0000226792.16216.1c.